The FDA recorded a supplement dated 10 September 2026 to Alembic's abbreviated new drug application for asenapine maleate (ANDA 206098). The record does not say what the supplement changes; supplements to generic applications are usually manufacturing, labelling-alignment or packaging changes.
Asenapine is a sublingual second-generation antipsychotic used for schizophrenia and bipolar mania. Nothing in this record signals a new indication or a safety finding. It matters mainly as part of the continuing supply of generic asenapine. Its regulatory and availability position in India is not stated in this record.
- Treat this as an administrative change to a generic licence, not a new indication or safety alert.
- Remind patients on asenapine to let the tablet dissolve under the tongue and avoid food or drink for 10 minutes.
- Continue metabolic monitoring as for any second-generation antipsychotic.
- Check local availability before switching brands; the Indian regulatory position is not given here.
Why it matters
Regulatory noise is easy to misread as a safety signal; this one is not.
Don't overread it
A licence supplement is not a new indication or a safety communication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free